An observational study in Overactive Bladder, sponsored by Stimuli Technology. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.
Sponsored by Stimuli Technology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Urinary Bladder, Overactive with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Urinary Bladder, Overactive · France.
Among the 53 studies in Urinary Bladder, Overactive with a site in France, this one is the 8th largest by enrollment of the 13 observational ones that give a count, is the only one that started in 2022, is one of 13 observational ones, and was the 45th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →6 of the 53 studies in Urinary Bladder, Overactive with a site in France are open now. Recruiting first, the newest first:
DJO UK Ltd · Sites in France
Ages 18+
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 6–16
Stimuli Technology · Sites in France, Italy, United Kingdom
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–99
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is below the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Median enrollment 267 across the 40 interventional studies, 100 across the 13 observational. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 53 have an industry lead sponsor. The 10 most frequent:
Stimuli Technology is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Stimuli Technology has 3 studies filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
2 of the studies in Urinary Bladder, Overactive with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05772637Assistance Publique - Hôpitaux de ParisClinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis | 2027-02-14 |
| NCT05949567Assistance Publique - Hôpitaux de ParisDoes Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population | 2027-04-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Urinary Bladder, Overactive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management. While effectiveness of TC-pTNS has been demonstrated in the literature, the success rate is heterogeneous, depending on the clinical picture. In an effort to ascertain clearly the efficacy of Tensi+ device, as well as its safety of use and assess comfort of use, the present study will evaluate the results of Tensi+ treatment in real life conditions in a prospective study. The main objective is to assess the efficacy (actual clinical benefit) of TC-pTNS with Tensi+ device for management of overactive bladder in an adult population at 3 months.
Included patients are prescribed a treatment with Tensi+ for 3 months. An evaluation visit is scheduled at 3 months. In treatment is continued, a follow-up visit is scheduled at 6 months.
Primary outcome measure
Success at 3 months defined as a composite parameter:
(i) Objective improvement, with at least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary AND (ii) Subjective improvement, with patient Global Impression of Improvement score of 1 or 2 Time point(s) at which primary outcome measure is assessed : 3 months Secondary outcome measures (i) Evaluation of urinary symptoms based on bladder diary parameters (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire (ii) Evaluation of adverse events (iii) Patient-reported Outcomes Measures (PROMs): Comfort of use (VAS in deciles), recommendation to another patient (binary), consumer grading regarding device usability details (iv) Quality of life measures (OABq questionnaire, VAS scale) (vii) Assessment of treatment persistence Time point(s) at which Secondary outcome measure is assessed* : at 3 months and 6 months
Inclusion criteria : Age ≥ 18 years Overactive bladder symptoms
Number of subjects : 100
Age ≥ 18 years Overactive bladder symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
Objective improvement
At least 30% decrease of urgency episodes compared to baseline on 3-day bladder diary
Time frame: At 3 months
Subjective improvement
Patient Global Impression of Improvement score of 1 or 2
Time frame: At 3 months
Evaluation of urinary symptoms
Bladder diary parameters evaluation (urinary frequency, incontinence episodes, maximum bladder capacity, nocturia episodes) and the Urinary Symptom Profile (USP) questionnaire
Time frame: At 3 months and 6 months
Evaluation of adverse events
Questions to be asked to patients at 3 months and 6 months if there were any adverse events during treatment
Time frame: At 3 months and 6 months
Patient-reported Outcomes Measures (PROMs)
Comfort of use, recommendation to another patient (binary), consumer grading regarding device usability details
Time frame: At 3 months and 6 months
Quality of life measures
By filling up OABq questionnaire and VAS scale
Time frame: At 3 months and 6 months
Assessment of treatment persistence
Time frame: At 3 months and 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in May 2023, 11 months.
Of 59 observational studies under Urinary Bladder, Overactive, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stimuli Technology